Cargando…

Strength of patient cohorts and biobanks for cardiomyopathy research

In 2011 the Netherlands Heart Foundation allocated funding (CVON, Cardiovasculair Onderzoek Nederland) to stimulate collaboration between clinical and preclinical researchers on specific areas of research. One of those areas involves genetic heart diseases, which are frequently caused by pathogenic...

Descripción completa

Detalles Bibliográficos
Autores principales:	de Boer, R. A., Nijenkamp, L. L. A. M., Silljé, H. H. W., Eijgenraam, T. R., Parbhudayal, R., van Driel, B., Huurman, R., Michels, M., Pei, J., Harakalova, M., van Lint, F. H. M., Jansen, M., Baas, A. F., Asselbergs, F. W., van Tintelen, J. P., Brundel, B. J. J. M., Dorsch, L. M., Schuldt, M., Kuster, D. W. D., van der Velden, J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Bohn Stafleu van Loghum 2020
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7419403/ https://www.ncbi.nlm.nih.gov/pubmed/32780332 http://dx.doi.org/10.1007/s12471-020-01456-4

Ejemplares similares

Protein Quality Control Activation and Microtubule Remodeling in Hypertrophic Cardiomyopathy
por: Dorsch, Larissa M., et al.
Publicado: (2019)

Untying the knot: protein quality control in inherited cardiomyopathies
por: Dorsch, Larissa M., et al.
Publicado: (2018)

Mutation location of HCM-causing troponin T mutations defines the degree of myofilament dysfunction in human cardiomyocytes
por: Schuldt, Maike, et al.
Publicado: (2021)

BIO FOr CARE: biomarkers of hypertrophic cardiomyopathy development and progression in carriers of Dutch founder truncating MYBPC3 variants—design and status
por: Jansen, M., et al.
Publicado: (2021)

Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations
por: Pei, J., et al.
Publicado: (2021)

Extra energy for hearts with a genetic defect: ENERGY trial
por: van Driel, B. O., et al.
Publicado: (2019)

Correction to: Extra energy for hearts with a genetic defect: ENERGY trial
por: van Driel, B. O., et al.
Publicado: (2019)

Cardiovascular genetics: technological advancements and applicability for dilated cardiomyopathy
por: Kummeling, G.J.M., et al.
Publicado: (2015)

Increasing sensitivity—a common-sense approach?
por: Michels, M., et al.
Publicado: (2019)

UNRAVEL: big data analytics research data platform to improve care of patients with cardiomyopathies using routine electronic health records and standardised biobanking
por: Sammani, A., et al.
Publicado: (2019)

Genotype‐specific pathogenic effects in human dilated cardiomyopathy
por: Bollen, Ilse A. E., et al.
Publicado: (2017)

Life-long tailoring of management for patients with hypertrophic cardiomyopathy: Awareness and decision-making in changing scenarios
por: Michels, M., et al.
Publicado: (2016)

Distinct Metabolomic Signatures in Preclinical and Obstructive Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Blood‐based biomarkers for the prediction of hypertrophic cardiomyopathy prognosis: a systematic review and meta‐analysis
por: Jansen, Mark, et al.
Publicado: (2022)

Proteomic and Functional Studies Reveal Detyrosinated Tubulin as Treatment Target in Sarcomere Mutation-Induced Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Metabolomics in Severe Aortic Stenosis Reveals Intermediates of Nitric Oxide Synthesis as Most Distinctive Markers
por: van Driel, Beau Olivier, et al.
Publicado: (2021)

Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants
por: Jansen, Mark, et al.
Publicado: (2023)

Molecular autopsy
por: van Driel, B., et al.
Publicado: (2018)

Sex-Related Differences in Protein Expression in Sarcomere Mutation-Positive Hypertrophic Cardiomyopathy
por: Schuldt, Maike, et al.
Publicado: (2021)

Risk stratification and subclinical phenotyping of dilated and/or arrhythmogenic cardiomyopathy mutation-positive relatives: CVON eDETECT consortium
por: Roudijk, R. W., et al.
Publicado: (2021)

Five-year prognostic significance of global longitudinal strain in individuals with a hypertrophic cardiomyopathy gene mutation without hypertrophic changes
por: van Velzen, H. G., et al.
Publicado: (2019)

Sex-specific cardiac remodeling in early and advanced stages of hypertrophic cardiomyopathy
por: Nijenkamp, Louise L. A. M., et al.
Publicado: (2020)

Author Correction: The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unresponsive to standard heart failure therapy
por: Eijgenraam, Tim R., et al.
Publicado: (2020)

The phospholamban p.(Arg14del) pathogenic variant leads to cardiomyopathy with heart failure and is unreponsive to standard heart failure therapy
por: Eijgenraam, Tim R., et al.
Publicado: (2020)

The Netherlands Arrhythmogenic Cardiomyopathy Registry: design and status update
por: Bosman, L. P., et al.
Publicado: (2019)

Genetic Basis of Dilated Cardiomyopathy in Dogs and Its Potential as a Bidirectional Model
por: Gaar-Humphreys, Karen R., et al.
Publicado: (2022)

Increased Myocardial Oxygen Consumption Precedes Contractile Dysfunction in Hypertrophic Cardiomyopathy Caused by Pathogenic TNNT2 Gene Variants
por: Parbhudayal, Rahana Y., et al.
Publicado: (2020)

Rationale and design of the PHOspholamban RElated CArdiomyopathy intervention STudy (i-PHORECAST)
por: te Rijdt, W. P., et al.
Publicado: (2021)

Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs
por: van Leeuwen, R W F, et al.
Publicado: (2013)

Protein Aggregation Is an Early Manifestation of Phospholamban p.(Arg14del)–Related Cardiomyopathy: Development of PLN-R14del–Related Cardiomyopathy
por: Eijgenraam, Tim R., et al.
Publicado: (2021)

Effect of body surface area and gender on wall thickness thresholds in hypertrophic cardiomyopathy
por: Huurman, R., et al.
Publicado: (2019)

P62‐positive aggregates are homogenously distributed in the myocardium and associated with the type of mutation in genetic cardiomyopathy
por: van der Klooster, Zoë Joy, et al.
Publicado: (2021)

The microtubule signature in cardiac disease: etiology, disease stage, and age dependency
por: Algül, Sıla, et al.
Publicado: (2023)

Massive expansion and cryopreservation of functional human induced pluripotent stem cell-derived cardiomyocytes
por: Maas, Renee G.C., et al.
Publicado: (2021)

A tailored approach towards informing relatives at risk of inherited cardiac conditions: study protocol for a randomised controlled trial
por: van den Heuvel, Lieke M, et al.
Publicado: (2019)

Impact of the COVID-19-pandemic on patients with gynecological malignancies undergoing surgery: A Dutch population-based study using data from the ‘Dutch Gynecological Oncology Audit’
por: Algera, M.D., et al.
Publicado: (2022)

Supporting the gastrointestinal microenvironment during high-dose chemotherapy and stem cell transplantation by inhibiting IL-1 signaling with anakinra
por: Wardill, H. R., et al.
Publicado: (2022)

Quantitative Approach to Fragmented QRS in Arrhythmogenic Cardiomyopathy: From Disease towards Asymptomatic Carriers of Pathogenic Variants
por: Roudijk, Rob W., et al.
Publicado: (2020)

The phospholamban (PLN) p.Arg14del risk model; Longitudinal validation and reevaluation of predictors regarding sudden cardiac death (SCD)
por: Van Der Heide, M Y C, et al.
Publicado: (2023)

Radiomics analysis of pre-treatment [(18)F]FDG PET/CT for patients with metastatic colorectal cancer undergoing palliative systemic treatment
por: van Helden, E. J., et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4jf8kbn8h1j2089f0tedteo9pi